375345-98-5

Upstream product

• 375345-97-4 propane-2-sulfonic acid (2-phenylpropyl)amide 
• 1823-91-2 1-phenylethyl cyanide 
• 20780-53-4 (R)-Styrene oxide 
• 34298-25-4 (R)-β-methylphenethylamine hydrochloride 
• 112424-29-0 (R)-2-(2-phenylpropyl)isoindoline-1,3-dione 
• 582-22-9 (R)-2-phenylpropylamine 
• 1123-85-9 (+)-(R)-2-phenylpropanol 
• 685876-10-2 (2R)-2-phenylpropylamine Malate 

Downstream Products

• 375345-95-2 {(2R)-2-[4-(4-{2-[(methylsulfonyl)amino]ethyl}phenyl)phenyl]-propyl}[(methylethyl)sulfonyl]amine 
• 516491-32-0 N,N'-([1,1'-biphenyl]-4,4'-diyldi-2,1-ethanediyl)-bis-methanesulfonamide 
• 7440-05-3 palladium 
• 400629-36-9 propane-2-sulfonic acid {2-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]propyl}amide 
• 1266112-09-7 C₁₉H₂₄F₃N₃O₄S 

Relevant academic research and scientific papers

Enantioselective Synthesis of β-Methyl Amines via Iridium-Catalyzed Asymmetric Hydrogenation of N-Sulfonyl Allyl Amines

The iridium-catalyzed asymmetric hydrogenation of several N-sulfonyl allyl amines is reported. All substrates can be easily obtained by the Ir-catalyzed isomerization of N-tosylaziridines reported previously. The commercially available threonine-derived phosphinite (UbaPHOX) iridium complex has been found to be the best catalyst for this catalytic application, affording β-methyl amines with good to excellent ee values (up to 94%). The synthetic potential of this novel methodology was demonstrated by the formal synthesis of Lorcaserin and LY-404187. (Figure presented.).

BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS

Embodiments of the invention are directed to compounds that are positive allosteric modulators of AMP A receptors.

Structure based evolution of a novel series of positive modulators of the AMPA receptor

Starting from compound 1, we utilized biostructural data to successfully evolve an existing series into a new chemotype with a promising overall profile, exemplified by 19.

AMPA RECEPTOR POTENTIATORS

The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.

Sulfonamide derivatives

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.

Combination therapy for treatment of depression

The present invention provides a method for treating depression, comprising administering to a patient an effective amount of a first component which is a suitable antidepressant, in combination with an effective amount of a second component which is a suitable AMPA receptor potentiator.

Heterocyclic sulfonamide derivatives

The present invention provides certain heterocyclic sulfonamide derivatives of formula (I): useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.

Process for preparing biphenyl compounds

The present invention relates to a process for the preparation of a biphenyl compound comprising combining a phenyl boronic acid derivative with an halobenzene derivative in the presence of a suitable additive in a suitable organic solvent with a suitable catalyst and a suitable base.